Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) traded down 0.4% during mid-day trading on Monday . The stock traded as low as $2.76 and last traded at $2.76. 68,617 shares were traded during trading, an increase of 3,069% from the average session volume of 2,165 shares. The stock had previously closed at $2.77.
Graybug Vision Price Performance
The stock’s 50-day moving average is $3.41 and its 200 day moving average is $4.09. The stock has a market cap of $4.49 million, a price-to-earnings ratio of -1.65 and a beta of 1.20.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Stories
- Five stocks we like better than Graybug Vision
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Expert Stock Trading Psychology Tips
- 2 Drone Stocks Surging from Increased Media Attention
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
